Philip R. Cohen, MD
The University of Houston Health Center, University of Houston, Houston, Texas; The Department of Dermatology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; and The Department of Dermatology, University of Texas–Houston Medical School, Houston, Texas

Disclosure: The author reports no relevant conflicts of interest. No sources of funding were used to assist in the preparation of this review. Read the rest of this article »

Eric W. Baum, MD, MSc
University of Alabama at Birmingham, Birmingham, Alabama

Abstract
When treating patients with extensive dermatitis, total body surface area affected must be considered when prescribing topical medication. Halcinonide 0.1% cream, a class 2 topical corticosteroid, is now available in a 216g jar. This large size is convenient and cost effective for patients with large-area dermatoses. Objectives: The objectives of this study were to determine the efficacy and patient acceptance of halcinonide in 216g jars for the treatment of large-area dermatoses. Design: This study was an open-label, noncomparator trial evaluating the clinical outcomes and acceptability of halcinonide in 216g jars. Halcinonide was prescribed twice daily for up to 28 days. Measurement: Severity of dermatoses was based on investigator observations at the baseline visit and again after 28 days. Patient satisfaction was evaluated based on a questionnaire completed at the conclusion of the study. Results: Total enrollment was 40 patients. Dermatoses affected an average of 12 percent body surface area. At baseline, all patients exhibited dermatoses rated as severe or moderate. Nearly half of patients were completely cleared or almost cleared by 28 days, with all patients noting at least some improvement. Most patients agreed that they liked the way the product spread on the skin (94.7%), and more than 80 percent found that it was neither sticky nor greasy. In more than 90 percent of cases, the investigator reported that halcinonide provided a shorter duration of therapy versus triamcinolone one-pound jars. Conclusion: Halcinonide 0.1% cream in 216g jars is effective and convenient for patients with large-area dermatoses.
(J Clin Aesthet Dermatol. 2011;4(4):29–33.) Read the rest of this article »

Uwe Wollina, MD; Yousef Bayyoud, MD; Thomas Kittner, MD; Eberhard Dürig, MD

Uwe Wollina, MD is from Department of Dermatology and Allergology; Yousef Bayyoud, MD is from Neurosurgical Unit, Department of Emergency and Reconstructive Surgery; Thomas Kittner, MD is from Department of Radiology; Eberhard Dürig, MD is from Institute of Pathology, “Georg Schmorl,” Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany

Disclosure: The authors report no relevant conflicts of interest. Read the rest of this article »

Laura Englander, MD; Jason J. Emer, MD; Danielle McClain, MD;
Bijal Amin, MD; Ryan B. Turner, MD

Laura Englander, MD and Ryan B. Turner, MD are from Department of Dermatology, Albert Einstein School of Medicine, Bronx, New York; Jason J. Emer, MD is from Department of Dermatology,
Mount Sinai School of Medicine, New York, New York; Danielle McClain, MD is from Department of Pathology, Albert Einstein School of Medicine, Bronx, New York Read the rest of this article »

Volker Meyer, MD; Tobias Goerge, MD; Thomas A. Luger, MD; Stefan Beissert, MD
Department of Dermatology, University of Münster, Münster, Germany

Disclosure: Dr. Luger has received an honorarium as a speaker for Basilea Pharmaceutica, Munich, Germany. Drs. Meyer, Goerge, and Beissert report no relevant conflicts of interest. This clinical research is supported by a restricted grant from Basilea Pharmaceutica, Munich, Germany. Read the rest of this article »

Andrea Losch, MD; Katherine D. Chilek, DO; Matthew J. Zirwas
Andrea Losch, MD and Matthew J. Zirwas are from The Ohio State University, Columbus, Ohio; Katherine D. Chilek, DO, is from Ohio University, Athens, Ohio

Disclosure: The authors report no relevant conflicts of interest. Read the rest of this article »